What are considerations for the use of chemotherapy in the treatment of soft tissue sarcoma?

Updated: Apr 29, 2019
  • Author: from Memorial Sloan-Kettering - Mrinal M Gounder, MD; Chief Editor: Edwin Choy, MD, PhD  more...
  • Print


See the list below:

  • Concurrent chemoradiation typicalliy is mainly used for extremity and trunk soft tissue sarcoma, as use in intra-abdominal/retroperitoneal sites has more significant toxicities.

  • Doxorubicin can be administered as a flat dose of 30 mg daily for 3 d, with concurrent radiation therapy.

  • Radiotherapy with ifosfamide is associated with significant toxicities, and full doses are difficult to administer beyond two cycles.

  • A single trial reported safe administration of gemcitabine at 700 mg/m2 along with 50 Gy over 25 fractions

  • There are sparse data on oral temozolomide 50 mg/m2 once daily for 7 d with radiation therapy (dose of 50.4 Gy)

  • Combination chemotherapy regimens (MAID [mesna, doxorubicin, ifosfamide, and dacarbazine]) with concurrent radiation therapy have higher response and prohibitive toxicities and therefore should be performed at centers with adequate experience with these regimens; there are no prospective studies comparing chemoradiation to radiation therapy alone

  • Consider adjuvant chemotherapy for chemosensitive, extremity/trunk, and high-risk lesions; consider age, performance status, size, grade, location, type of initial surgery, and margin status when discussing initiation of adjuvant therapy

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!